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Breast cancer is the commonest cancer among women in the
Western world, with the cumulative lifetime risk in Denmark
being 1 in 12 (Danish Board of Health, 1997). Together with
ovarian cancer, breast cancer constitutes almost one-third of all
incident cancers among women (non-melanoma skin cancer
excluded). The association of elevated risks for breast and ovarian
cancers with a family history of these malignancies is well estab-
lished (Amos and Struewing, 1993; Eby et al, 1994; Newman et al,
1997; Pharoah et al, 1997). The overall likelihood that a first-
degree female relative of a breast cancer patient will develop
breast or ovarian cancer is estimated to be two to three and three to
four times higher, respectively, than that of other women. In many
of these families, genetic determinants play a major role. It has
been estimated that approximately 3% of all breast cancers and
4—5% of ovarian cancers occur among the 0.1—0.3% of women in
the general population who carry germline mutations of the
BRCA1 susceptibility gene (Claus et al, 1991; Ford et al, 1995;
Whittemore et al, 1997). Among women with breast cancer before
the age of 35, the gene carrier prevalence is even higher, probably
about 7—13% (FitzGerald et al, 1996; Langston et al, 1996),
although recent population-based studies of young affected
women without a positive family history suggest prevalences that
are of the order of 6% (Malone et al, 1998). The BRCA1 gene
seems to have a high lifetime penetrance: approximately 55—75%
for the breast cancer phenotype and 15—30% for the ovarian cancer
phenotype (Struewing et al, 1997; Whittemore et al, 1997). The
penetrance estimates from broader population studies tend to be
lower than the estimates from families selected for linkage. In
addition, familial breast cancer, especially at early ages, has been
linked to germline mutations of the BRCA2 gene as well as the p53
gene in Li—Fraumeni syndrome and the PTEN gene in Cowden￿s
disease (Gudmundsson et al, 1996; Rebbeck et al, 1996; Crook et
al, 1997; Krainer et al, 1997 Li et al, 1997). The ATM gene also
has been suspected to play a role in breast cancer occurrence
(Bebb et al, 1997), although the evidence is not convincing for
early-onset breast cancer (FitzGerald et al, 1997).
A familial tendency to breast cancer has been reported in asso-
ciation with other cancers, including those of the endometrium,
prostate and colon (Tulinius et al, 1992a; Goldar et al, 1994;
Sellers et al, 1994), but the evidence is inconclusive and has not
been fully assessed in population-based incidence studies. Among
some populations, the risk of prostate cancer is increased in
BRCA1 and  BRCA2 carriers (Struewing et al, 1997).
PATIENTS AND METHODS
A population-based study of breast cancer in Denmark was
conducted to quantify the risk for a second primary cancer among
early-onset breast cancer patients and to investigate the risks for
breast and other cancers among first-degree relatives.
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Summary Inherited susceptibility to breast cancer is associated with an early onset and bilateral disease. The extent of familial risks has not,
however, been fully assessed in population-based incidence studies. The purpose of the study was to quantify the risks for cancers of the
breast, ovary and other sites of close relatives of women in whom breast cancer was diagnosed at an early age. Records collected between
1943 and 1990 at the Danish Cancer Registry were searched, and 2860 women were found in whom breast cancer was diagnosed before
age 40. Population registers and parish records were used to identify 14 973 parents, siblings and offspring of these women. Cancer
occurrence through to 31 December 1993 was determined within the Cancer Registry’s files and compared with national incidence rates.
Women with early-onset breast cancer were at a nearly fourfold increased risk of developing a new cancer later in life (268 observed vs 68.9
expected). The excess risk was most evident for second cancer of the breast (181 vs 24.5) and for ovarian cancer (20 vs 3.3). For mothers
and sisters, risks for cancers of the breast and ovary were significantly increased by two- to threefold. Bilateral breast cancer and
breast–ovarian cancer were very strong predictors of familial risks, with one in four female relatives predicted to develop breast and/or ovarian
cancer by age 75. Mothers had a slightly increased risk of colon cancer, but not endometrial cancer. The risk for breast cancer was also
increased among fathers (standardized incidence ratio 2.5; 95% CI 0.5–7.4) and especially brothers (29; 7.7–74), although based on small
numbers. The risk for prostatic cancer was unremarkable. In this large population-based survey, the first-degree relatives of women who
developed breast cancer before age 40 were prone to ovarian cancer as well as male and female breast cancer, but not other tumours that
may share susceptibility genes with breast cancer.
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During 1943—90, breast cancer was diagnosed in 2860 women
born in 1935 or later before they reached 40 years of age. These
early-onset breast cancer patients were identified from the files of
the Danish Cancer Registry, which also provided the patients￿
names, dates of birth and unique personal identification numbers.
The last, which incorporates sex and date of birth and permits
accurate linkage of information between registers, was available
for 2850 women alive on 1 April 1968, when the Central
Population Register (CPR) was established in Denmark and for
one woman born after that date. Linkage to the files of the CPR
provided information on the date of death or date of emigration.
For nine women who died before 1 April 1968, the date of death
was obtained manually from the Death Certificate File at the
National Board of Health. Nearly 40% of the women studied were
under the age of 35 when their breast cancer was diagnosed 
(Table 1).
Identifying relatives
Parents of these women were identified in one of two ways. When
the personal identification number was available, computerized
linkage with the files of the CPR readily identified the name, iden-
tification number and date of death or emigration (if applicable) of
each parent. If the breast cancer patients or one or both of the
parents had died before 1 April 1968, information about the
parents had to be obtained manually from ￿parish registries￿, that is
the population registers of the localities in which the families had
lived at the date of birth of the cancer patient. Parents identified in
this manner were then traced by computer in the CPR (parents of
the nine breast cancer patients who died before 1 April 1968) or
traced manually in the Death Certificate File (parents deceased
before 1 April 1968) to verify personal data and dates of death.
This parental search revealed that 20 pairs of the young breast
cancer patients were sisters. Overall, 2670 different mothers
(94%) and 2587 different fathers (91%) were found (Table 2).
Sisters and brothers of the women with early-onset breast cancer
were also located in the files of the CPR by using the personal
identification number of the mother or from local parish registers.
For the 20 pairs of sisters with early-onset breast cancer, the sister
who was youngest at the time of diagnosis was regarded as the
proband of the family. A total of 2156 sisters and 2354 brothers (of
2840 probands) were identified. The offspring of the young breast
cancer patients were located through the CPR from the personal
identification number of their mother. A total of 2544 daughters
and 2662 sons (likewise of 2840 probands) were identified.
Identifying cancer in patients and relatives
Data on the women with early-onset breast cancer and their rela-
tives were linked with the Danish Cancer Registry, using the study
subjects￿ personal identification numbers or, if they had died
before 1 April 1968, their date of birth, date of death and name.
The period of follow-up for the occurrence of cancer among
women with early-onset breast cancer extended from the date of
the initial breast cancer to the date of death or emigration or until
31 December 1993, whichever came first. The period of follow-up
for the occurrence of cancer among parents extended from the date
of birth of the proband with breast cancer, and that among siblings
and offspring from the date of birth to the date of death or emigra-
tion to 31 December 1993. Cancers, including benign tumours of
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Table 1 Selected characteristics of the 2860 women with early-onset
breast cancer in Denmark, 1943–90
Characteristic Number %
Breast cancer patients 2860 100
Year of birth
1935–44 1194 42
1945–54 1453 51
1955–68 213 7
Year of diagnosis
1953–62 7 <1
1963–72 248 9
1973–82 1321 46
1983–90 1284 45
Age at diagnosis
10–14 1 <1
15–19 2 <1
20–24 39 1
25–29 271 10
30–34 807 28
35–39 1740 61
Vital status as of 31 December 1993
Alive 1581 55
Dead 1270 44
Emigrated 9 <1
a Includes 20 pairs of sisters with early-onset breast cancer.
Table 2 Year of birth and vital status for 14 973 first-degree relatives of 2840 probands with early-onset breast cancer
Relationship Number located Year of birth Vital statusa
(range) Alive Dead Emigrated
No. % No. % No. %
Mothers 2670 1890–1949 1602 60 1061 40 7 <1
Fathers 2587 1865–1949 1007 39 1569 61 11 <1
Sistersb 2156 1910–1979 1932 90 177 8 47 2
Brothers 2354 1910–1974 2094 89 206 9 54 2
Daughters 2544 1950–1993 2456 96 22 1 66 3
Sons 2662 1950–1993 2563 96 60 2 39 2
All relatives 14973 1890–1993 11654 78 3095 21 224 1
aAs of 31 December 1993. bIncludes 20 sisters with early-onset breast cancer.the brain and papillomas of the urinary tract, were classified
according to the modified Danish verion of the International
Classification of Diseases, 7th Revision (ICD-7) (World Health
Organization, 1957). The national incidence rates for these cate-
gories of tumour, calculated according to sex, age (in 5- year
groups), and 5- year historical periods, were applied to the
person—years of observation for each study cohort to obtain the
number of cancers that would have been expected if they had had
the same rates of incidence as the general population.
Statistical analysis
The statistical methods were chosen on the basis of the assumption
that the observed number of cases of cancer in any specific cate-
gory follows a Poisson distribution. Significance and confidence
intervals for the standardized incidence ratio (SIR) — the ratio of
the observed to the expected number of cancers — were calculated,
with use of the Miettinen exact confidence limits if the observed
number of cases was small; otherwise, an accurate asymptotic
approximation was used (Rothman and Boice, 1979). Account was
also taken of the age of the proband at the time of the initial diag-
nosis of breast cancer and the age of the relatives at the time of
cancer diagnosis. Separate analyses were performed for relatives
of probands with contralateral breast cancer (n = 201) and
probands with a second primary cancer of the ovary (n = 20).
RESULTS
Second malignant neoplasms
Breast cancer was diagnosed in almost 60 women per year before
the age of 40 during the years 1943—90 in Denmark. A total of 2860
patients accrued 23 000 person—years of follow-up (average 8.0
years; range >0—39.5 years), during which time 268 new primary
cancers developed, with 68.9 expected, yielding a SIR of 3.9 (95%
CI 3.4—4.4) (Table 3) and a cumulative risk after 25-years of follow-
up of 31%. The excess 200 cancers consisted mainly of tumours of
the contralateral breast (SIR 7.4; n181) and ovarian cancer (SIR 6.0;
n 20). A small but significant increase in risk was seen for cancers at
all other sites combined (SIR 1.6). The risk for cancer of the
endometrium was elevated (SIR 2.7) but not significantly. Cancer of
the lung was significantly elevated (SIR 2.7), as was the risk of
cancer of the liver though based on only two cases. Thyroid cancer
was increased but not significantly, based on only two cases.
Twenty-one women with synchronous bilateral cancer were not
included in the risk estimates for second primary breast cancers.
Female relatives
The 2670 mothers of women with early-onset breast cancer repre-
sented nearly 110 000 person—years of follow-up (average 41
years; range >0—51 years). The 2156 sisters represented some 
93 000 person—years (average 43 years; range >0—51 years). Over
the entire follow-up period, 889 malignancies were diagnosed in
mothers and 196 in sisters, yielding SIRs of 1.3 (95% CI 1.2—1.4)
and 1.6 (1.4—1.8) respectively (Table 4). Significant excess risks
were seen for cancers of the breast (mothers SIR 2.0; sisters 2.6),
ovary (mothers 1.7; sisters 1.9), and other sites combined (mothers
1.1). The mothers also had significantly increased risks for cancers
of the cervix (SIR 1.4) and colon (SIR 1.2), whereas the SIR for
cancer of the brain (0.6) was below that expected. No other signi-
ficant deviations were seen among mothers or sisters, although
seven cases of leukaemia were observed among sisters with 3.0
expected.
The cumulative risk for breast or ovarian cancer in the mothers
was 3.8% vs 1.5% expected at the 20-year follow-up point and
12.1% v 6.2% expected at 40 years. The cumulative risk in sisters
was 1.7% v 0.6% at 40 years.
A total of 2544 daughters of women with early-onset breast
cancer were identified, representing approximately 56 000
person—years of follow-up. Their average age in 1993, however,
was only 21.6 years. Nine cancers were observed compared with
10.7 expected, yielding a SIR of 0.8 (95% CI 0.4—1.6). Of these,
two were breast cancer, diagnosed at the ages of 26 and 31,
compared with 0.4 expected (SIR 5.0; 95% CI 0.4—18). Two cases
of leukaemia (1.7 expected) and one case of brain cancer (2.3
expected) occurred in daughters, whereas no bone or connective
tissue sarcomas were seen (data not shown).
The relative risks for cancers of the breast (Table 5) and ovary
(Table 6) among first-degree female relatives were inversely
related to the age at diagnosis of early-onset breast cancer in the
proband. That is, the younger the proband, the higher the risks for
breast and ovarian cancers in her mother and sisters. Further, there
was a tendency for these tumours to occur earlier in life if the
proband was diagnosed with breast cancer at an early age. The
occurrence of bilateral breast cancer or breast plus ovarian cancer
in a proband was a strong predictor of breast and ovarian cancers
among female relatives (Table 7). Of the 201 probands with bilat-
eral breast cancer, 31 of their 191 mothers (16%) and 25 of their
186 sisters (13%) developed cancers of the breast or ovary. Of the
20 probands with breast cancer and subsequent ovarian cancer, 8
of their 19 mothers (42%) and 5 of their 23 sisters (22%) also
developed one of these malignancies.
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Table 3 Standardized incidence ratios (SIRs) of second malignant
neoplasms (SMN) of the breast, ovary and other sites among 2860 women
with early-onset breast cancer, 1943–90, and follow-up through 1993
Site of SMN (ICD-7 code) Obs Exp SIR 95% CI
All malignant neoplasms (140–204) 268 68.9 3.9 3.4–4.4
Breasta (170) 181 24.5 7.4 6.4–8.6
Ovary (175) 20 3.3 6.0 3.7–9.2
All other sites combined 67 41.1 1.6 1.3–2.1
Endometrium (172) 5 1.8 2.7 0.9–6.4
Cervix uteri (171) 9 6.8 1.3 0.6–2.5
Buccal cavity and pharynx (140–148) 1 0.7 1.5 0.0–8.1
Stomach (151) 2 0.7 3.0 0.3–11
Colon (153) 5 2.3 2.2 0.7–5.2
Rectum (154) 3 1.1 2.8 0.6–8.1
Liver (155) 2 0.2 9.4 1.1–34
Biliary tract (155.1) 0 0.2 0.0 0.0–18.4
Pancreas (157) 1 0.6 1.8 0.8–9.9
Larynx (161) 0 0.2 0.0 0.0–18.4
Lung (162) 9 3.3 2.7 1.2–5.2
Urinary system (180,181) 2 1.5 1.3 0.2–4.8
Melanoma of skin (190) 5 4.1 1.2 0.4–2.8
Non-melanoma of skin (191) 13 8.7 1.5 0.8–2.6
Brain (193) 4 2.8 1.4 0.4–3.7
Thyroid (194) 2 0.7 3.0 0.3–10.8
Lymphatic and haematopoietic 4 2.7 1.5 0.4–3.8
tissues (200–204)
Other and unspecified sites 0 2.7 0.0 0.0–1.4
Obs, number of cases observed; Exp, number of cases expected. aExcluding
21 women with synchronous, bilateral breast cancer.Figure 1 shows the cumulative risk of breast or ovarian cancer
by the age of the mothers and sisters up to age 75 years, compared
with corresponding risk estimates for the general population.
Approximately 15% (one in seven) of mothers and sisters of
women with early-onset breast cancer were diagnosed with breast
or ovarian cancer before age 75 vs 8% (1 in 12) in the general
population. The familial risk increased from 14% when the
probands were diagnosed at ages 35—39 to 18% when the probands
were diagnosed under the age of 35. The cumulative incidence by
age 75 reached 24% (one in four) among mothers and sisters of
probands with bilateral breast cancer or with breast and subse-
quent ovarian cancer.
Male relatives
Among the 2587 fathers of women with early-onset breast cancer
(person—years of follow-up 97000; average 37 years; range,
0.3—51 years), 798 cancers were recorded, with 744.7 expected,
yielding an SIR of 1.1 (Table 8). Among the 2354 brothers
(person—years of follow-up, 101000; average 43 years; range
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Table 4Standardized incidence ratios (SIRs) for cancer in mothers and sisters of 2840 probands with early-onset breast cancer
Site of cancer (ICD-7 code) Mothers (n = 2670) Sisters (n = 2156)
Obs Exp SIR 95%CI Obs Exp SIR 95% CI
All malignant neoplasms (140–204) 889 680.4 1.3 1.2–1.4 196 123.9 1.6 1.4–1.8
Breast (170) 291 147.5 2.0 1.8–2.2 92 35.8 2.6 2.1–3.2
Ovary (175) 64 38.5 1.7 1.3–2.1 12 6.5 1.9 1.0–3.3
All other sites combined 534 494.4 1.1 1.0–1.2 92 81.6 1.1 0.9–1.4
Endometrium (172) 38 40.6 0.9 0.7–1.3 6 4.4 1.4 0.5–3.0
Cervix uteri (171) 84 60.0 1.4 1.2–1.7 15 13.5 1.1 0.6–1.8
Buccal cavity and pharynx 9 7.6 1.2 0.5–2.3 3 1.4 2.1 0.4–6.1
(140–148)
Stomach (151) 17 17.1 1.0 0.6–1.6 1 1.4 0.7 0.0–3.9
Colon (153) 67 53.8 1.2 1.0–1.6 5 4.9 1.0 0.3–2.4
Rectum (154) 30 27.3 1.1 0.8–1.6 2 2.3 0.9 0.1–3.1
Liver (155) 4 4.3 0.9 0.3–2.4 0 0.5 0.0 0.0–7.4
Biliary tract (155.1) 8 7.9 1.0 0.4–2.0 1 0.5 2.1 0.0–12
Pancreas (157) 12 17.6 0.7 0.4–1.2 1 1.3 0.8 0.0–4.3
Larynx (161) 4 2.2 1.8 0.5–4.7 0 0.4 0.0 0.0–9.2
Lung (162) 48 44.8 1.1 0.8–1.4 12 7.0 1.7 0.9–3.0
Kidney (180) 19 15.9 1.2 0.7–1.9 0 1.8 0.0 0.0–2.0
Bladder (181) 12 17.3 0.7 0.4–1.2 2 1.8 1.1 0.1–4.0
Melanoma of skin (190) 12 14.1 0.9 0.4–1.5 4 6.6 0.6 0.2–1.6
Non-melanoma of skin (191) 75 67.4 1.1 0.9–1.4 12 13.1 0.9 0.5–1.6
Brain (193) 10 17.8 0.6 0.3–1.0 7 5.9 1.2 0.5–2.4
Bone and connective tissue (196, 197) 2 2.9 0.7 0.1–2.5 1 1.2 0.8 0.0–4.6
Non-Hodgkin’s lymphoma (200, 202) 16 11.4 1.4 0.8–2.3 3 2.3 1.3 0.3–3.8
Hodgkin’s disease (201) 4 2.7 1.5 0.4–3.8 1 1.5 0.7 0.0–3.7
Multiple myeloma (203) 7 6.1 1.2 0.5–2.4 0 0.5 0.0 0.0–7.4
Leukemia (204) 9 12.5 0.7 0.3–1.4 7 3.0 2.3 0.9–4.8
Other and unspecified sites 47 43.1 1.1 0.8–1.5 9 6.3 1.4 0.7–2.7
Obs, number observed; Exp, number expected.
Table 5Standardized incidence ratios (SIRs) of breast cancer among first-
degree female relatives (mothers and sisters) of probands by age of the
relative and by age of the proband when her own breast cancer was
diagnosed
Age of female relative (years)
Age of proband
at diagnosis <40 40–59 ³60 All ages
(years) SIR Obs SIR Obs SIR Obs SIR Obs
<30 7.1a  10 1.8a 17 2.2a 15 2.3a 42
30–34 4.4a 16 2.7a 68 1.7a 33 2.4a 117
35–39 2.2a 17 2.1a 118 1.7a 89 1.9a 224
All ages 3.3a 43 2.2a 203 1.7a 137 2.1a 383
Obs, number of cases observed. aP<0.05.
Table 6Standardized incidence ratios (SIRs) of breast cancer among first-
degree female relatives (mothers and sisters) of probands by age of the
relative and by age of the proband when her own breast cancer was
diagnosed
Age of female relative (years)
Age of proband
at diagnosis <40 40–59 ³60 All ages
(years) SIR Obs SIR Obs SIR Obs SIR Obs
<30 2.8 1 3.7a 8 0.6 1 2.3a 10
30–34 7.6a 7 3.1a 18 1.4 7 2.7a 32
35–39 1.0 2 1.419 1.013 1.234
All ages 3.1a 10 2.1a 45 1.021 1.7a 76
Obs, number of cases observed. aP<0.05>0—51 years), 107 cancers were seen, with 89.6 expected, yielding
a SIR of 1.2. Most prominent were the risks for breast cancer
among the fathers (SIR 2.5; 95% CI 0.5—7.4) and brothers (29;
7.7—74), although based on small numbers. Significantly increased
risks were also seen for cancer of the buccal cavity and pharynx
(SIR 1.4), non-melanoma skin cancer (1.2), and non-Hodgkin￿s
lymphoma (1.6) in fathers.
A total of 2662 sons of women with early-onset breast cancer
were found, representing approximately 58 000 person—years.
Their average age in 1993 was only 21.8 years. Nine cancers were
observed, with 13.4 expected, yielding an SIR of 0.7 (95% CI
0.3—1.3). Three cases of malignant melanoma were seen compared
with 0.5 expected (SIR 6.4; 1.3—19). There were no cases of male
breast cancer, leukaemia, sarcoma or brain cancer.
Childhood tumours
A total of 127 000 person—years of follow-up were accrued during
childhood, i.e. ages 0—14 in the combined group of daughters and
sons (73 500 person—years) and sisters and brothers (53 500
person—years). Overall, 26 cancers were observed, with 16.8
expected (SIR 1.6; 95% CI 1.0—2.3). Of these, nine were
leukaemias vs 5.5 expected (1.6; 0.8—3.1), six were brain tumours
vs 4.9 expected (1.2; 0.5—2.7), three were non-Hodgkin￿s
lymphomas vs 1.0 expected (2.9; 0.6—8.5), two were Hodgkin￿s
disease vs 0.5 expected (4.3; 0.5—16), and two were cancers of the
buccal cavity and pharynx vs 0.2 expected (13; 1.5—48). The
remaining four cases consisted of a mediastinal tumour, liver
cancer (not specified as primary), cutaneous melanoma, and
cancer of unspecified site. There were no sarcomas of bone or
connective tissue.
DISCUSSION
Women who develop breast cancer before the age of 40 are at very
high risk of developing a subsequent breast or ovarian cancer, with
the overall relative risk reaching sevenfold in our study. This
substantial excess risk is probably due to genetic predisposition,
although radiotherapy given to young patients may contribute to
the occurrence of contralateral breast cancer (Boice et al, 1992;
Storm et al, 1992). For mothers and sisters of women with early-
onset breast cancer, the overall relative risk for breast and ovarian
cancer was twofold, and the cumulative risk at 75 years of age was
15% in comparison with 8% expected in the general female popu-
lation of Denmark. Consistent with other studies of families with
breast and ovarian cancers (Claus et al, 1990; Slattery and Kerber,
1993; Teare et al, 1994; Peto et al, 1996), the earlier the age at
onset of breast cancer in the proband, the greater the familial risk
of breast or ovarian cancer. The lifetime risk rose further, to about
24%, when the proband had bilateral breast cancer or subsequent
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Table 7 Standardized incidence ratios (SIRs) of cancers of the breast, ovary and other sites combined among
first-degree female relatives (mothers and sisters) of 201 and 20 probands with bilateral breast cancer or a
second primary cancer of the ovary respectively
Probands with cancer of
Bilateral breasta (n = 201) Breast and ovary (n = 20)
Cancer sites in
female relatives Obs Exp SIR 95% CI Obs Exp SIR 95% CI
Mothers
Breast 26 10.2 2.6 1.7–3.8 3 0.9 3.2 0.7–9.5
Ovary 5 2.7 1.9 0.6–4.3 5 0.2 20.4 6.6–47
Other sites 31 34.8 0.9 0.6–1.3 5 3.2 1.6 0.5–3.6
Sisters
Breast 21 3.4 6.1 3.8–9.4 5 0.6 9.2 3.0–21
Ovary 4 0.6 6.4 1.7–16 0 0.1 0.0 0.0–37
Other sitesb 13 7.9 1.7 0.9–2.8 1 1.2 0.8 0.0–4.6
Mothers and sisters
Breast 47 13.6 3.5 2.5–4.6 8 1.5 5.4 2.3–11
Ovary 9 3.3 2.7 1.2–5.2 5 0.3 15.5 5.0–36
Other sites 44 42.7 1.0 0.8–1.4 6 4.4 1.4 0.3–3.2
Obs, number observed; Exp, number expected; aIncludes 21 women with synchronous, bilateral early-onset
breast cancer and one pair of sisters both with bilateral breast cancer, of whom only the sister first diagnosed is
regarded as the proband; b Includes three cases of cervical cancer (1.3 expected) two cases of endometrial
cancer (0.4 expected) and four cases of skin cancer (1.9 expected)
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Figure 1 Cumulative risk for breast and ovarian cancer in mothers and
sisters of probands who developed either bilateral breast cancer or breast
plus ovarian cancer ( ); who developed breast cancer before age 35 (+);
and who developed breast cancer when 35–39 years of age( ); compared
with the expected percentage in the general population (–)ovarian cancer. These results cannot readily be explained by recall
or selection bias, because all family members during a 50-year
period in the entire country of Denmark were identified from
national population and church registers, and cancer occurrence
was determined from national cancer registry files.
Germline mutations of the BRCA1 susceptibility gene are esti-
mated to account for about 3% of all breast cancers and 4—5% of
all ovarian cancers (Ford et al, 1995; Whittemore et al, 1997). If all
of the excess breast and ovarian cancers in the mothers of women
who developed breast cancer under the age of 40 in our study were
associated with inherited mutations, 6.3% of the mothers (169 of
2670) would have transmitted a susceptibility gene to their daugh-
ters. Taking into account that some women with family histories
may have mutations in genes other than BRCA1, this estimate is
consistent with the approximately 6—13% prevalence of BRCA1
mutations found in sporadic cases of breast cancer in women
under the age of 35 (FitzGerald et al, 1996; Langston et al, 1996;
Struewing et al, 1996; Malone et al, 1998), with about half of the
mutations inherited from mothers and half from fathers.
Population studies in Iceland and the United Kingdom have also
reported familial aggregation of incident or fatal cases of breast
and ovarian cancers in relatives of young breast cancer patients,
with relative risks similar to those we observed (Anderson et al,
1992; Tulinius et al, 1992b; Teare et al, 1994; Peto et al, 1996).
Some population and family studies of breast cancer have also
suggested excess risks for cancers of the colon (Goldgar et al,
1994), endometrium (Anderson et al, 1992; Tulinius et al, 1992a;
Peto et al, 1996), and prostate (Tulinius et al, 1992b; Anderson
and Badzich, 1993; Sellers et al, 1994; Tulinius et al, 1994;
Struewing et al, 1997), but our findings are consistent with studies
(Schildkraut et al, 1989; Negri et al, 1997) showing no elevated
risk for these tumours except possibly colon cancer in mothers.
The excess risk for cervical cancer we observed in mothers did not
extend to the sisters or daughters and probably represents a chance
occurrence. A significant increase in the risk for lung cancer
among the probands may be related to radiotherapy (Inskip et al,
1994) rather than to inherited factors, although a slight non-
significant increase in the risk for lung cancer was noted in
mothers and sisters suggesting familial patterns of tobacco use.
Despite its rarity, the risk of male breast cancer was signifi-
cantly elevated in accord with family studies indicating a genetic
susceptibility to male and female breast cancer, due especially to
germline mutations of BRCA2 (Stratton and Wooster, 1996). The
gene for Cowden￿s disease has recently been identified as PTEN
(Li et al, 1997), and may contribute to familial occurrences of
breast cancer as well as thyroid cancer.
In Li—Fraumeni syndrome, mutations in the p53 gene are
responsible for the familial constellation of early-onset breast
cancers and other tumours of young people, notably sarcomas of
soft tissue and bone, acute leukaemia, brain tumours and adreno-
cortical neoplasms (Li et al, 1988; Garber et al, 1991; Varley et al,
1997). In a previous population-based incidence study of cancer
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Table 8 Standardized incidence ratios (SIRs) for cancer in fathers and brothers of 2840 probands with early-
onset breast cancer
Site of cancer (ICD-7 code) Father (n = 2587) Brothers (n = 2354)
Obs Exp SIR 95% CI Obs Exp SIR 95% CI
All malignant neoplasms 798 744.7 1.1 1.0–1.2 107 89.6 1.2 1.0–1.4
(140–204)
Breast (170) 3 1.2 2.5 0.5–7.4 4 0.1 28.9 7.7–74
Prostate (177) 76 76.9 1.0 0.8–1.2 2 2.1 1.0 0.1–3.5
Testis (178) 9 5.6 1.6 0.7–3.0 5 8.7 0.6 0.2–1.3
Buccal cavity and pharynx 31 21.9 1.4 1.0–2.0 6 3.6 1.7 0.6–3.7
(140–148)
Stomach (151) 41 40.1 1.0 0.7–1.4 3 2.3 1.3 0.3–3.8
Colon (153) 50 52.6 1.0 0.7–1.3 6 4.3 1.4 0.5–3.1
Rectum (154) 41 43.3 1.0 0.7–1.3 2 2.0 0.7 0.1–2.4
Liver (155) 5 7.9 0.6 0.2–1.5 0 0.7 0.0 0.0–5.3
Biliary tract (155.1) 5 5.3 1.0 0.3–2.2 0 0.4 0.0 0.0–9.2
Pancreas (157) 30 23.4 1.3 0.9–1.8 2 1.7 1.2 0.1–4.3
Larynx (161) 13 12.2 1.1 0.6–1.8 1 1.5 0.7 0.0–3.7
Lung (162) 149 146.2 1.0 0.9–1.2 9 9.9 0.9 0.4–1.7
Kidney (180) 27 23.6 1.1 0.8–1.7 4 2.8 1.5 0.4–3.7
Urinary bladder (181) 75 65.0 1.2 0.9–1.5 4 5.3 0.8 0.2–1.9
Melanoma of skin (190) 9 9.8 0.9 0.4–1.7 8 4.4 1.8 0.8–3.6
Non-melanoma of skin 122 91.9 1.3 1.1–1.6 18 12.9 1.4 0.8–2.2
(191)
Brain (193) 16 17.6 0.9 0.5–1.5 8 6.5 1.2 0.5–2.4
Bone and connective tissue 2 3.1 0.6 0.1–2.3 3 1.7 1.8 0.4–5.2
(196, 197)
Non-Hodgkin’s lymphoma 22 14.1 1.6 1.0–2.4 4 3.5 1.1 0.3–2.9
(200, 202)
Hodgkin’s disease (201) 3 4.2 0.7 0.1–2.8 6 2.6 2.3 0.8–5.0
Multiple myeloma (203) 4 8.5 0.5 0.1–1.2 0 0.7 0.0 0.0–5.3
Leukemia (204) 19 19.9 1.0 0.6–1.5 7 4.4 1.6 0.6–3.3
Other and unspecified sites 46 50.4 0.9 0.7–1.2 5 7.5 0.7 0.2–1.6
Obs, number observed; Exp, number expected.risks among the parents of all children with cancer in Denmark, we
were able to detect a familial association between early-onset
breast cancer and childhood sarcoma (Olsen et al, 1995). The
current approach covered nearly 50 years of breast cancer inci-
dence in Denmark, but still had insufficient statistical power to
thoroughly assess the constellation of tumours associated with rare
genetic conditions such as Li—Fraumeni syndrome.
Thus, our population-based survey of cancer incidence among
close relatives of women with early-onset breast cancer in
Denmark suggests that susceptibility genes to breast cancer
contribute to only a small percentage of non-mammary malignan-
cies other than those of the ovary.
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